Le Registre des lobbyistes
Objets | Détails | Catégories |
---|---|---|
Economic Development,
Health
|
Organon Canada’s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including biosimilar drugs and women’s health products, which are the company’s main sectors of activities.
|
Legislative Proposal, Bill or Resolution,
Regulation
|
Health
|
Representations relating to the conditions under which biosimilar drugs are marketed and reimbursed in Canada. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current women’s health programs, the integration of biosimilar drugs into the drug plans administered by the Federal Government and to emphasize the importance that the federal government respect their respective jurisdiction with respect to the approval, marketing and reimbursement of Organon's products.
|
Policies or Program
|
Health
|
To actively promote the enhancement of publicly funded women’s health initiatives and programs, including the development of a Pan Canadian Women’s Health Strategy.
|
Policies or Program
|
Economic Development,
Health
|
To actively promote the value of the pharmaceutical industry for Canada's economic health and well being, but more importantly for the health and well being of its citizens and to propose solutions for integrated health care in Canada.
|
Policies or Program
|
Economic Development,
Health
|
To recommend policies that will attract increased investment in the pharmaceutical and well being industry, such as on policies, research programs and policies and the Innovation Agenda.
|
Policies or Program
|
Objets | Détails | Catégories |
---|---|---|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
Organon Canada’s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including biosimilar drugs and women’s health products, which are the company’s main sectors of activities.
|
Legislative Proposal, Bill or Resolution,
Regulation
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
Representations relating to the conditions under which biosimilar drugs are marketed and reimbursed in Canada. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current women’s health programs, the integration of biosimilar drugs into the drug plans administered by the Federal Government and to emphasize the importance that the federal government respect their respective jurisdiction with respect to the approval, marketing and reimbursement of Organon's products.
|
Policies or Program
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
Representations relating to the conditions under which biosimilar drugs are marketed and reimbursed in Canada. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current women’s health programs, the integration of biosimilar drugs into the drug plans administered by the Federal Government and to emphasize the importance that the federal government respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs.
|
Policies or Program
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
To actively promote the enhancement of publicly funded women’s health initiatives and programs, including the development of a Pan Canadian Women’s Health Strategy.
|
Policies or Program
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
To actively promote the value of the pharmaceutical industry for Canada's economic health and well being, but more importantly for the health and well being of its citizens and to propose solutions for integrated health care in Canada.
|
Policies or Program
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
To recommend policies that will attract increased investment in the pharmaceutical and well being industry, such as on policies, research programs and policies and the Innovation Agenda.
|
Policies or Program
|
Techniques de communication déjà utilisées ou qui seront utilisées au cours de l'engagement :